OnKure Therapeutics (OKUR) Liabilities and Shareholders Equity (2020 - 2026)

OnKure Therapeutics (OKUR) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $198.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 98.93% year-over-year to $198.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $419.7 million (up 13.08% YoY) and the FY2025 annual result came in at $62.1 million, down 45.94% from the prior year.
• Liabilities and Shareholders Equity grew to $198.7 million in Q1 2026, from $62.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $198.7 million in Q1 2026 to a low of $35.7 million in Q4 2023.
• A 5-year average of $105.7 million and a median of $99.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 66.97% — and 2024, when it surged 221.56%.
• Tracing OKUR's Liabilities and Shareholders Equity over 5 years: stood at $108.2 million in 2022, then sank by 66.97% to $35.7 million in 2023, then surged by 221.56% to $114.9 million in 2024, then sank by 45.94% to $62.1 million in 2025, then surged by 219.87% to $198.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $198.7 million (Q1 2026), $62.1 million (Q4 2025), and $72.8 million (Q3 2025), per Business Quant data.